TSLA
Tesla
-- 418.100 NVDA
NVIDIA
-- 137.340 AVGO
Broadcom
-- 180.660 PLTR
Palantir
-- 73.200 ADBE
Adobe
-- 474.630 
News
$Relmada Therapeutics (RLMD.US)$ Reuters· 2 mins ago
Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial Is Futile at Its Interim Analysis and Is Unlikely to Meet the Primary Efficacy Endpoint With Statistical Significance
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Trytosaveabit OP : Watching for the overreaction! (((((. The DMC did not identify any new safety concerns
Relmada to evaluate potential next steps for the REL-1017 program
Relmada to continue to focus on the development of REL-P11 for metabolic disease
Relmada is well capitalized with approximately $54.1 million in cash and cash equivalents as of September 30, 2024
dSuu : whoa, definitely hit the over react button lol, gm gl today
dSuu dSuu : I'm not in but that makes me happy lol bagging enough lately
Lnova : Overreaction play
Trytosaveabit OP Lnova : Indeed